Nurix Therapeutics, Gilead Sciences, Targeted Protein Degradation, Protein Degrader, Oncology, Cancer, E3 Ligase, Drug Discovery, Drug Development, GS-6791

BRISBANE, Calif. — October 5, 2026 Nurix Therapeutics, Inc. announced that it and Gilead Sciences have agreed to extend...